Darunavir accord

Package leaflet: Information for the user

Darunavir Accord, 400 mg, film-coated tablets
Darunavir Accord, 800 mg, film-coated tablets
Darunavirum
Read this leaflet carefully before taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. See section 4.

Contents of the leaflet

1. What Darunavir Accord is and what it is used for
2. What you need to know before taking Darunavir Accord
3. How to take Darunavir Accord
4. Possible side effects
5. How to store Darunavir Accord
6. Contents of the pack and other information

1. What Darunavir Accord is and what it is used for

What is Darunavir Accord?
Darunavir Accord contains the active substance darunavir. Darunavir Accord is an antiretroviral medicine used in the treatment of human immunodeficiency virus (HIV) infection.
It belongs to a group of medicines called protease inhibitors. Darunavir Accord works by reducing the amount of HIV in the body. This helps the immune system and reduces the risk of developing HIV-related illnesses.

What is it used for?
Darunavir Accord 400 mg and 800 mg tablets are used to treat HIV-infected adults and children (aged 3 years and older and weighing more than 40 kg) who:

• have not previously been treated with antiretroviral medicines, or
• in some patients who have previously been treated with antiretroviral medicines (your doctor will decide).

Darunavir Accord must be taken together with a low dose of cobicistat or ritonavir and other antiretroviral medicines for HIV. Your doctor will decide the most appropriate combination of medicines for you.

Tell your doctor about all medicines you are taking, including those taken orally, by inhalation, by injection, or applied to the skin.

2. What you need to know before taking Darunavir Accord

Do not take Darunavir Accord:

• if you are allergic to darunavir, or to any of the other ingredients of this medicine (listed in section 6), or to cobicistat or ritonavir;
• if you have severe liver problems. If you are unsure about liver conditions or their nature, consult your doctor. Additional tests may be required.

Do not take Darunavir Accord with the following medicines:
If you are taking any of the medicines listed below, talk to your doctor about changing your treatment.

Products containing St John’s wort ( Hypericum perforatum ) must not be used during treatment with Darunavir Accord.
Warnings and precautions
Before starting treatment with Darunavir Accord, discuss this with your doctor, pharmacist, or nurse.
Darunavir Accord will not cure HIV infection.
Patients taking Darunavir Accord remain at risk of developing infections or other illnesses associated with HIV, therefore regular contact with a doctor should be maintained.
Skin rash may occur in patients treated with Darunavir Accord. Rarely, this rash may become severe or potentially life-threatening. If a rash occurs, contact your doctor immediately.
Skin rash (usually mild or moderately severe) may occur more frequently in patients taking Darunavir Accord together with raltegravir for the treatment of HIV infection, compared to patients taking either drug alone.
When to inform the doctor about your health status BEFORE and DURING treatment
After reviewing the points below, the patient should inform the doctor if any of them apply.

• Inform your doctor if you have previously had liver disease , including hepatitis B or C virus infection. Your doctor will assess the severity of the condition before deciding whether Darunavir Accord can be taken.
• Inform your doctor if you have diabetes . Darunavir Accord may increase blood sugar levels.
• Inform your doctor immediately if you notice signs of infection (e.g. swollen lymph nodes, fever). In some patients with advanced HIV infection and a history of opportunistic infections, inflammatory symptoms related to previous infections may appear shortly after starting antiretroviral therapy. These symptoms are believed to result from an enhanced immune response, enabling the body to fight previously asymptomatic infections.
• In addition to opportunistic infections, autoimmune disorders (conditions where the immune system attacks healthy body tissues) may also occur after starting antiretroviral therapy for HIV infection. Autoimmune disorders may develop several months after starting treatment. If you experience symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and progressing towards the trunk, palpitations, tremors, or hyperactivity, contact your doctor immediately to initiate necessary treatment.
• Inform your doctor if you have haemophilia . Darunavir Accord may increase the risk of bleeding.
• Inform your doctor about hypersensitivity to sulfonamides (used, for example, in the treatment of certain infections).
• Inform your doctor about musculoskeletal disorders . In some patients receiving combination antiretroviral therapy, a bone disease called osteonecrosis (bone tissue death due to impaired blood supply) may develop. Risk factors for osteonecrosis include: prolonged use of combination antiretroviral therapy, corticosteroid use, alcohol consumption, profound immunosuppression, increased body mass index, and others. Symptoms of osteonecrosis include: joint pain and stiffness (particularly in hips, knees, or shoulders) and difficulty moving. Inform your doctor if any of these symptoms occur.

Elderly patients
Darunavir Accord has been used in only a small number of patients aged 65 years or older.
If you belong to this age group, consult your doctor to discuss the possibility of taking this medicine.
Children
Darunavir Accord 400 mg, 800 mg tablets are not intended for children under 3 years of age or weighing less than 40 kg.
Darunavir Accord and other medicines
Inform your doctor or pharmacist about all medicines you are currently taking or have recently taken.
Some medicines must not be combined with Darunavir Accord. A list of these medicines is provided in the section “Do not take Darunavir Accord with the following medicines”.
In most cases, Darunavir Accord can be used together with anti-HIV medicines from other classes [e.g.: NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists, and FIs (fusion inhibitors)]. Studies have not been conducted on the concomitant use of Darunavir Accord with cobicistat or ritonavir and all PIs (protease inhibitors), and it must not be used in combination with other protease inhibitors. In some cases, dosage adjustments of other medicines may be necessary. Therefore, always inform your doctor about taking other anti-HIV medicines and strictly follow the doctor’s instructions regarding concomitant use of other medicines.
The effectiveness of Darunavir Accord may be reduced when taken simultaneously with any of the following products. Inform your doctor if you are taking:

• phenobarbital, phenytoin (anticonvulsants);
• dexamethasone (corticosteroid);
• efavirenz (HIV-1 infection);
• rifapentine, rifabutin (antituberculosis agents);
• saquinavir (HIV-1 infection).

Taking Darunavir Accord may affect the effectiveness of other medicines. Your doctor may order additional blood tests. Inform your doctor if you are taking:

• amlodipine, diltiazem, disopyramide, carvedilol, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nifedipine, nicardipine, propafenone, timolol, verapamil (cardiovascular medicines), due to the potential for increased therapeutic effects and adverse reactions of these drugs;
• apixaban, dabigatran etexilate, edoxaban, rivaroxaban, warfarin, clopidogrel (anticoagulants), due to the potential for increased therapeutic effects and adverse reactions of these drugs;
• hormonal contraceptives and hormone replacement therapies containing oestrogens; Darunavir Accord may reduce their effectiveness; to avoid unintended pregnancy, use of alternative non-hormonal methods of contraception is recommended;
• ethinylestradiol with drospirenone . Darunavir Accord may increase the risk of elevated potassium levels associated with drospirenone;
• atorvastatin, pravastatin, rosuvastatin (cholesterol-lowering medicines). There is an increased risk of muscle damage. Your doctor will evaluate which cholesterol-lowering medicine is appropriate for you in this situation;
• clarithromycin (antibiotic);
• cyclosporine, everolimus, tacrolimus, sirolimus (immunosuppressive medicines), due to the potential for increased therapeutic effects and adverse reactions of these drugs;
• corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone . These medicines are used to treat allergies, asthma, inflammatory bowel diseases, skin, eye, joint, and muscle inflammation, and other inflammatory conditions. These medicines are usually taken orally, inhaled, injected, or applied to the skin. If no alternative medicines are available, use of these drugs is possible only after evaluation by the doctor and under strict monitoring for corticosteroid-related adverse effects by the treating physician;
• buprenorphine/naloxone (medicines used in opioid addiction treatment);
• salmeterol (a medicine used in the treatment of asthma);
• artemether/lumefantrine (combination medicine used in the treatment of malaria);
• dasatinib, everolimus, irinotecan, nilotinib, vinblastine, vincristine (medicines used in cancer treatment);
• sildenafil, tadalafil, vardenafil (medicines used in erectile dysfunction or in the treatment of heart and lung disorders, so-called pulmonary arterial hypertension);
• glecaprevir/pibrentasvir (used in the treatment of hepatitis C virus infection);
• fentanyl, oxycodone, tramadol (painkillers);
• fesoterodine, solifenacin (in the treatment of urological disorders).

Concomitant administration of other medicines with Darunavir Accord may affect their therapeutic effects and adverse reactions. Therefore, your doctor may order additional blood tests, and dosage adjustments of other medicines may be required.
Inform your doctor if you are taking:

• dabigatran etexilate, edoxaban, warfarin (medicines affecting blood coagulation);
• alfentanil (for injection, a strong, short-acting painkiller used in surgical procedures);
• digoxin (a medicine used in the treatment of certain heart conditions);
• clarithromycin (antibiotic);
• itraconazole, isavuconazole, fluconazole, posaconazole, clotrimazole (antifungal medicines). Voriconazole may be taken only after consultation with a doctor;
• rifabutin (medicine against bacterial infections);
• sildenafil, vardenafil, tadalafil (medicines for erectile dysfunction or pulmonary hypertension);
• amitriptyline, desipramine, imipramine, nortriptyline, paroxetine, sertraline, trazodone (antidepressants and anxiolytics);
• maraviroc (medicine used in HIV infection);
• methadone (medicine used in opioid addiction treatment);
• carbamazepine, clonazepam (medicines used to prevent seizures or in the treatment of certain types of neuropathic pain);
• colchicine (in the treatment of gout or familial Mediterranean fever);
• bosentan (medicine used in the treatment of pulmonary hypertension);
• buspirone, chlordiazepoxide, diazepam, estazolam, flurazepam, midazolam administered by injection, zolpidem (sedatives);
• perphenazine, risperidone, thioridazine (antipsychotics);
• metformin (medicine for type 2 diabetes).

This is not a complete list of medicines. Inform your doctor about all medicines you are taking.
Darunavir Accord with food and drink
See section 3 “How to take Darunavir Accord”.
Pregnancy and breastfeeding
Inform your doctor immediately if you are pregnant or planning to become pregnant. Pregnant women should not take Darunavir Accord with ritonavir without specific medical advice.
Pregnant women should not take Darunavir Accord with cobicistat.
Due to the potential for adverse effects in breastfed infants, women should not breastfeed while taking Darunavir Accord.
Breastfeeding is not recommended for HIV-infected women, as HIV can be transmitted to the child through breast milk. If you are breastfeeding or considering breastfeeding, consult your doctor immediately.
Driving and using machines
Do not drive or operate machinery if Darunavir Accord causes dizziness.
Darunavir Accord 400 mg film-coated tablets contain sunset yellow (E110) , which may cause allergic reactions.
Darunavir Accord 400 mg film-coated tablets contain lactose
This medicine contains lactose. If you have been previously diagnosed with intolerance to certain sugars, consult your doctor before taking this medicine.
Darunavir Accord 400 mg film-coated tablets contain propylene glycol
This medicine contains 55.55 mg of propylene glycol in each film-coated tablet.
If the child being treated is less than 4 weeks old, talk to the treating doctor or pharmacist before administering this medicine, especially if the child is receiving other medicines containing propylene glycol or alcohol.
Darunavir Accord 800 mg film-coated tablets contain lactose
This medicine contains lactose. If you have been previously diagnosed with intolerance to certain sugars, consult your doctor before taking this medicine.
Darunavir Accord 800 mg film-coated tablets contain propylene glycol
This medicine contains 111.1 mg of propylene glycol in each film-coated tablet.
If the child being treated is less than 4 weeks old, talk to the treating doctor or pharmacist before administering this medicine, especially if the child is receiving other medicines containing propylene glycol or alcohol.

3. How to take Darunavir Accord

This medicine should always be taken exactly as described in this patient leaflet or as directed by your
doctor, pharmacist, or nurse. If in doubt, consult your doctor, pharmacist, or nurse. Even if a noticeable
improvement occurs, do not stop taking Darunavir Accord together with cobicistat or ritonavir without
consulting your doctor.

Do not change the dose, formulation, or stop treatment without your doctor's advice once treatment has started.
Darunavir Accord 400 mg tablets are intended only for use in creating an 800 mg once-daily dosing regimen.
Darunavir Accord 800 mg tablets are intended only for once-daily administration.

Dosage for adults who have not previously taken antiviral medicines (to be determined by your
doctor)
The usual dose of Darunavir Accord is 800 mg (two 400 mg tablets or one 800 mg tablet) once daily.
You must take Darunavir Accord every day, always together with cobicistat 150 mg or ritonavir 100 mg, and with food. Darunavir Accord will not provide the desired therapeutic effect if taken without cobicistat or ritonavir and without food.
Eat a meal or snack within 30 minutes before taking Darunavir Accord and cobicistat or ritonavir. The type of food does not matter. Even if a noticeable improvement occurs, do not stop taking Darunavir Accord with cobicistat or ritonavir without consulting your doctor.

Instructions for adults

• Take two 400 mg tablets at the same time, once daily (every day).
• Always take Darunavir Accord at the same time as 150 mg cobicistat or 100 mg ritonavir.
• Take Darunavir Accord with food.
• Swallow the tablets with water or milk.
• Take other anti-HIV medicines in combination with Darunavir Accord and cobicistat or ritonavir as directed by your doctor.
• An oral suspension containing 100 milligrams of darunavir per millilitre is also available for use in children, which may in certain cases also be used in adults.

Dosage for adults who have previously taken antiviral medicines (to be determined by your
doctor)
The dose is:

• 800 mg Darunavir Accord (two 400 mg tablets or one 800 mg tablet) together with 150 mg cobicistat or 100 mg ritonavir once daily. OR
• 600 mg Darunavir Accord together with 100 mg ritonavir twice daily.

Discuss with your doctor which dose is appropriate for you.

Dosage for children aged 3 years and older taking ritonavir, and aged 12 years and older taking
cobicistat, weighing at least 40 kilograms, who have not previously taken antiretroviral medicines (to be determined by your doctor)

• The recommended dose of Darunavir Accord is 800 mg (two 400 mg tablets or one 800 mg tablet) together with ritonavir 100 mg or cobicistat 150 mg once daily.

Dosage for children aged 3 years and older taking ritonavir, and aged 12 years and older taking
cobicistat, weighing at least 40 kilograms, who have previously taken antiretroviral medicines (to be determined by your doctor)
The dose is:

• 800 mg Darunavir Accord (two 400 mg tablets or one 800 mg tablet) together with 100 mg ritonavir once daily. OR
• 600 mg Darunavir Accord together with 100 mg ritonavir twice daily.

Discuss with your doctor which dose is appropriate for you.

Instructions for children aged 3 years and older taking ritonavir, and aged 12 years and older taking cobicistat, weighing at least 40 kilograms

• Take the 800 mg dose of Darunavir Accord (two 400 mg tablets or one 800 mg tablet) at the same time each day, once daily.
• Always take Darunavir Accord at the same time as 100 mg ritonavir.
• Take Darunavir Accord with food.
• Swallow the tablets with water or milk.
• Take other anti-HIV medicines in combination with Darunavir Accord and ritonavir as directed by your doctor.

Opening the child-resistant cap
The plastic bottle is equipped with a child-resistant cap.

To open it, follow these steps:

• Press down on the plastic cap while turning it counterclockwise;
• Remove the loosened cap.

Taking more Darunavir Accord than recommended
Contact your doctor, pharmacist, or nurse immediately.

Missing a dose of Darunavir Accord
If you notice you have missed a dose within 12 hours, take the missed tablets as soon as possible. Each dose must be taken with ritonavir and food. If you notice you have missed a dose after 12 hours, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a missed dose.

If you vomit after taking Darunavir Accord and cobicistat or ritonavir
If you vomit within 4 hours of taking the medicine, take another dose of Darunavir Accord and cobicistat or ritonavir as soon as possible, together with food. If you vomit more than 4 hours after taking the medicine, do not take another dose of Darunavir Accord and cobicistat or ritonavir until your next scheduled dose.

If you are unsure about what to do if you miss a dose or vomit, contact your doctor.

Do not stop taking Darunavir Accord without consulting your doctor
HIV medicines may make you feel better, but even if you feel improvement, do not stop taking the medicine without first discussing it with your doctor.
If you have any further questions about the use of this medicine, consult your doctor, pharmacist, or nurse.

4. Possible adverse reactions

During HIV treatment, increases in body weight, as well as blood lipid and glucose levels, may occur. This is partly related to improved health and lifestyle, and in the case of blood lipid levels, sometimes to the antiretroviral therapy itself. Your doctor will order tests to monitor these changes.

Like all medicines, this medicine can cause adverse reactions, although not everybody experiences them.
If any of the described adverse reactions occur, you should inform your doctor.

Hepatic complications have been reported, which in rare cases may be severe. Your doctor will order a blood test before starting treatment with Darunavir Accord. If you have chronic viral hepatitis B or C, your doctor should order blood tests more frequently, as there is an increased risk of hepatic complications. You should discuss with your doctor the symptoms of liver dysfunction, which may include: yellowing of the skin or eyes, dark urine (tea-colored), pale stools (faeces), nausea, vomiting, loss of appetite, or pain, discomfort or tenderness in the right upper abdomen.

Skin rash (more commonly occurring when used concomitantly with raltegravir), itching. Skin rash is usually mild to moderate in severity. However, skin rash may also be a sign of a rare but serious condition. Therefore, if a rash occurs, you should consult your doctor. Your doctor will decide on appropriate symptomatic treatment or whether to discontinue Darunavir Accord.

Other serious adverse reactions included: diabetes (frequent) and pancreatitis (uncommon).

Very common adverse reactions (may occur in more than 1 in 10 patients):

• Diarrhoea

Common adverse reactions (may occur in up to 1 in 10 patients):

• Vomiting, nausea, abdominal pain or bloating, indigestion, flatulence;
• Headache, fatigue, dizziness, somnolence, numbness, tingling or pain in hands or feet, weakness, difficulty sleeping.

Uncommon adverse reactions (may occur in up to 1 in 100 patients):

• Chest pain, changes in ECG, rapid heart rate;
• Sensory disturbances or reduced sensation, tingling, difficulty concentrating, memory loss, balance disorders;
• Difficulty breathing, cough, nosebleeds, throat irritation;
• Gastritis or oral inflammation, heartburn, retching (without vomiting), dry mouth, abdominal discomfort, constipation, belching;
• Renal failure, kidney stones, difficulty urinating, frequent or excessive urination, sometimes at night;
• Urticaria, severe swelling of the skin and other tissues (most commonly lips or eyes), rash, excessive sweating, night sweats, hair loss, acne, scaly skin, pigmentation of nails;
• Muscle pain, muscle cramps or reduced muscle strength, limb pain, osteoporosis;
• Slowed thyroid activity, which may be detected by blood test results;
• Hypertension, sudden flushing of the face;
• Redness or dryness of the eyes;
• Fever, swelling of the lower limbs due to fluid retention, feeling unwell, irritability, pain;
• Infections, herpes;
• Erectile dysfunction, breast enlargement in men;
• Sleep disorders, drowsiness, depression, anxiety, strange dreams, decreased libido.

Rare adverse reactions (may occur in up to 1 in 1000 patients):

• DRESS syndrome [severe rash associated with fever, fatigue, facial swelling or swollen lymph nodes, increased eosinophil count (a type of white blood cell), and liver, kidney or lung involvement];
• Heart attack, slow heart rate, palpitations;
• Visual disturbances;
• Chills, malaise;
• Feeling confused or disoriented, mood changes, restlessness;
• Fainting, seizures, changes or loss of taste;
• Mouth pain, vomiting blood, inflammation of the lips, dry lips, coated tongue;
• Catarrh;
• Skin disorders, dry skin;
• Muscle or joint stiffness, joint pain with or without inflammation;
• Blood cell count and biochemical test abnormalities. Changes may be observed in blood or urine tests. Your doctor will provide detailed explanations. An example is an increase in a certain type of white blood cells;
• Darunavir crystals in the kidneys causing kidney disease.

Adverse reactions typical of antiretroviral medicines in the same class as Darunavir Accord include:

• Muscle pain, tenderness or weakness. In rare cases, such disorders may be severe.

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Reactions of Medicinal Products at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw
Tel: +48 22 4921 301, Fax: +48 22 4921 309, Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
Reporting adverse reactions helps provide more information on the safety of this medicine.

5. How to store Darunavir Accord

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and bottle after "EXP". The expiry date refers to the last day of the specified month.
No special storage precautions are required for Darunavir Accord.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Such measures help protect the environment.

6. Contents of the pack and other information

What Darunavir Accord contains

• The active substance is darunavir. Each Darunavir Accord 400 mg coated tablet contains 400 mg of darunavir (as darunavir propylene glycol solvate).

Each Darunavir Accord 800 mg coated tablet contains 800 mg
of darunavir (as darunavir propylene glycol solvate).

• Other ingredients are:

Darunavir Accord, 400 mg, coated tablets
Monohydrate lactose, microcrystalline cellulose, povidone K30, crospovidone, colloidal anhydrous silica, magnesium stearate.
Coating Coating (orange-2): polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), brilliant black FCF, aluminium lake (E110).
Darunavir Accord, 800 mg, coated tablets
Monohydrate lactose, microcrystalline cellulose, povidone K30, crospovidone, colloidal anhydrous silica, magnesium stearate.
Coating Coating (red): polyvinyl alcohol (E1203), macrogol 3350 (E1521), red iron oxide (E172), talc (E553b), titanium dioxide (E171).
What Darunavir Accord looks like and contents of the pack
Darunavir Accord, 400 mg, coated tablets
Light orange, oval tablets with the engraved mark "400" on one side,
measuring: length 18.2 ± 0.2 mm, width 9.2 ± 0.2 mm, and thickness 5.7 ± 0.4 mm.
Darunavir Accord, 800 mg, coated tablets
Dark red, oval tablets with the engraved mark "800" on one side,
measuring: length 21.4 ± 0.2 mm, width 10.8 ± 0.2 mm, and thickness 8.0 ± 0.4 mm.
Carton box containing a white, opaque high-density polyethylene (HDPE) bottle
with a child-resistant polypropylene cap and a seal, together with a leaflet.
Pack sizes:
Darunavir Accord, 400 mg, coated tablets
One bottle containing 60 tablets.
Darunavir Accord, 800 mg, coated tablets
One or three bottles containing 30 tablets each.
Not all pack types may be marketed.
Marketing Authorisation Holder
Accord Healthcare Polska Sp. z o.o.
Taśmowa 7 Street
02-677 Warsaw
Tel: +48 22 577 28 00
Manufacturer / Importer
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park
Paola, PLA3000
Malta
Pharmathen International S.A.
6, Dervenakion Street
Pallini, Attiki, 153 51
Greece
Pharmathen International S.A.
Industrial Park Sapes
Rodopi Prefecture, Block No 5
Rodopi, 69300
Greece
LABORATORI FUNDACIÓ DAU
C/ C, 12-14 Pol. Ind. Zona Franca,
Barcelona, 08040
Spain
This medicinal product is authorised in the Member States of the European Economic Area under the following names: